5-chloro-7-iodo-2H-pyrazolo[3,4-c]pyridine, 98%, 250mg

Tapón con vidrio hueco cónico estándar, 45/40, 1 Pieza

(S)-(-)-Trityl glycidyl ether, 95.0%, 25g

Ethyl 4-bromo-7-methoxy-1H-pyrrolo[2,3-c]pyridine-2-carboxylate, 98%, 100mg

2-Hydrazino-1H-benzimidazole, 95.0%, 5g

1-Methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid, 95.0%, 250mg

1,3-diiodobicyclo[1.1.1]pentane, 97.0%, 1g

2-(2,3-Dihydrobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 1g

2,3,4,6-Tetra-O-acetyl-alpha-D-galactopyranosyl 2,2,2-Trichloroacetimidate>95.0%(HPLC)1g

5-Bromo-2-hydroxy-3-(trifluoromethyl)pyridine, 95.0%, 25g

Hexamethylene Diisocyanate>98.0%(GC)25mL

2-(5-Bromo-2-thienyl)ethylamine, 97%, 250mg

2-Benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane>97.0%(GC)5g